Cat. No.: HY-116940

Sm4

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Sm4 is a selective and orally active SOX18 inhibitor. Sm4 inhibits SOX18-DNA binding (IC₅₀ = 97.5 μM); Sm4 disrupts the SOX18-RBPJ protein-protein interaction (IC₅₀ = 42.3 μM). Sm4 blocks SOX18 DNA binding, disrupts multiple SOX18 protein-protein interactions with RBPJ, DDX1, DDX17, ILF3, SOX7 and STAT1, modulates SOX18 chromatin binding dynamics. Sm4 exerts anti‑angiogenic and anti‑lymphangiogenic effects, reduces tumor vascular density, triggers vascular defects in zebrafish, prolongs survival in mouse metastatic cancer models. Sm4 can be used for the research of breast cancer.

For research use only. We do not sell to patients.

Purity: 99.01%
CAS No.: 365542-77-4
Formula: C₁₉H₁₆O₃
Molecular Weight:292.33

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Sm4 Chemical Structure

CAS No.: 365542-77-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

STAT1

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	CC₅₀	>100 μM Compound: 14a	Cytotoxicity against HEK293 cells after 24 hrs by resazurin assay Cytotoxicity against HEK293 cells after 24 hrs by resazurin assay	[PMID: 23416004]
HepG2	CC₅₀	>100 μM Compound: 14a	Cytotoxicity against human HepG2 cells after 24 hrs by resazurin assay Cytotoxicity against human HepG2 cells after 24 hrs by resazurin assay	[PMID: 23416004]

In Vitro

Sm4 (0.2 μM-3 mM) inhibits full-length mouse SOX18-DNA binding with an IC₅₀ of 97.5 μM in a FP competition assay, with no aggregation observed up to 1000 μM^[1].
Sm4 (0.3-300 μM; 1 h) selectively disrupts SOX18-RBPJ interactions with IC₅₀ values of 42.3 μM^[1].
Sm4 inhibits DNA binding of multiple SOX family HMG-box fragments with IC₅₀ values of 200-300 μM, showing a slight preference for SOX18 and SOX15^[1].
Sm4 (24 h) inhibits SOX18-dependent Vcam-1 promoter transcriptional activity in COS-7 cells with an IC₅₀ of 5.2 μM, with a CC₅₀ of 117 μM^[1].
Sm4 alters SOX18 chromatin binding dynamics in live cells, increasing the specific bound fraction and dwell time of specifically bound SOX18 in a concentration-dependent manner^[1].
Sm4 (25 μM) can selectively dysregulate SOX18-mediated transcription in human umbilical vein endothelial cells (HUVECs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sm4 (1-2 μM; exposure in culture medium) selectively inhibits SoxF transcriptional activity and arteriovenous specification in zebrafish larvae, with no effect on Sox9-mediated chondrogenesis^[1].
Sm4 (5-50 mg/kg; p.o.; daily; 10 days) dose-dependently improves survival and reduces metastasis in a mouse model of breast cancer by inhibiting tumor-induced angiogenesis and lymphangiogenesis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

tg(-6.5kdrl:eGFP); tg(Dll4in3:eGFP); tg(fli1a:eGFP,-6.5kdrl:mCherry); tg(col2a1:YFP)^[1]
Dosage:

1 μM (tg(-6.5kdrl:eGFP) larvae); 2 μM (tg(Dll4in3:eGFP) larvae); 1.5 μM (vascular phenotype assays)
Administration:

exposure in culture medium; initiated at 20 hpf (tg(-6.5kdrl:eGFP) larvae); initiated at 13 hpf (tg(Dll4in3:eGFP) larvae); initiated at 16 hpf (vascular phenotype assays); continuous from 2 to 6 days post fertilization (tg(col2a1:YFP) larvae)
Result:

Reduced SOX18-dependent egfp transcript levels by 61% in tg(-6.5kdrl:eGFP) larvae.
Repressed Dll4in3:eGFP reporter activity in tg(Dll4in3:eGFP) larvae.
Caused arteriovenous specification defects and significant reductions in efnb2a, hey1, and efnb4a expression at 24 and 48 hpf in vascular phenotype assays.
Did not perturb Sox9-dependent tg(col2a1:YFP) reporter activity or chondrogenesis.

Animal Model:

BALB/c wild-type (6-10 weeks old; inoculated with 4T1.2 mammary carcinoma cells)^[1]
Dosage:

5-50 mg/kg/day
Administration:

p.o.; daily; 10 days (days 3-12)
Result:

Prolonged median survival of tumor-bearing mice from 33 days (control) to 44 days (25 mg/kg/day) and 73 days (50 mg/kg/day).
Decreased lung metastatic lesions by 67% at day 28 under 25 mg/kg/day administration.
Reduced tumor endothelial cell number by 48%, blood vessel volume by 55%, lymphatic vessel density by 65%, and lymphatic endothelial cell number by 70% with 25 mg/kg/day treatment.
Exerted no significant influence on primary tumor size.

Chemical Information

CAS No. 365542-77-4
Appearance Solid
Molecular Weight 292.33
Formula C₁₉H₁₆O₃
Color Off-white to light brown
SMILES

O=C(C1=C(C=CC=C1O)CCC2=CC=C3C=CC=CC3=C2)O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti-angiogenic Therapy in Armored and Cold Tumors. [Abstract]

2025 Jan 17:e2409147. PMID: 39823457

Solvent & Solubility

In Vitro:

DMSO : 12.5 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4208 mL

17.1040 mL

34.2079 mL

5 mM

0.6842 mL

3.4208 mL

6.8416 mL

10 mM

0.3421 mL

1.7104 mL

3.4208 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Francois M. Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases, WO, WO2018112545A1, 2018-06-28.

[2]. Mamidyala SK, et al. Efficient synthesis of anacardic acid analogues and their antibacterial activities. Bioorg Med Chem Lett. 2013;23(6):1667-1670. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4208 mL	17.1040 mL	34.2079 mL	85.5198 mL
	5 mM	0.6842 mL	3.4208 mL	6.8416 mL	17.1040 mL
	10 mM	0.3421 mL	1.7104 mL	3.4208 mL	8.5520 mL
	15 mM	0.2281 mL	1.1403 mL	2.2805 mL	5.7013 mL
	20 mM	0.1710 mL	0.8552 mL	1.7104 mL	4.2760 mL
	25 mM	0.1368 mL	0.6842 mL	1.3683 mL	3.4208 mL
	30 mM	0.1140 mL	0.5701 mL	1.1403 mL	2.8507 mL
	40 mM	0.0855 mL	0.4276 mL	0.8552 mL	2.1380 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sm4

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) Sm4

All STAT Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Sm4 Related Classifications

Cat. No.: HY-116940